Matthew Shields - 18 Jun 2026 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Reporting relationship: EVP, Global Operations
Issuer ticker: TEVA
Reported as of: 18 Jun 2026
Net transaction value: -$321,547
SEC form: 4
Accepted by SEC: 22 Jun 2026, 16:00:55 UTC
Prior SEC filing: 04 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Dov Bergwerk as attorney-in-fact for Matthew Shields

Key filing fact

Matthew Shields filed Form 4 for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) on 22 Jun 2026.

Key facts

This page summarizes Matthew Shields's Form 4 filing for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 22 Jun 2026, 16:00.

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

CIK 0002025621 Primary reporting owner

Relationship: EVP, Global Operations
Address: C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 124 DVORA HANEVI'A ST.,, TEL AVIV, ISRAEL
Signature: /s/ Dov Bergwerk as attorney-in-fact for Matthew Shields
Signature date: 22 Jun 2026

Shares, units, or other non-derivative securities reported in this filing.

TEVA transaction

Sale

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Explanation of responses 1 footnote

Footnote F1

The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.